Literature DB >> 19609461

The role of X-box binding protein-1 in tumorigenicity.

Ayesha N Shajahan1, Rebecca B Riggins, Robert Clarke.   

Abstract

Rapid growth of a tumor can overwhelm the vasculature that supplies it with nutrients and oxygen. Inside such tumors, cells undergo endoplasmic reticulum stress but can survive such adverse microenvironments by an adaptive mechanism called the unfolded protein response (UPR). X-box binding protein-1 (XBP-1) is a critical transcriptional activator of the UPR and is responsible for regulating the function of genes in cell survival. An unconventional splicing of the XBP-1(U) messenger RNA (mRNA) results in two proteins: XBP-1(S) that is often increased in a variety of human cancers and any translated proteins from the unspliced XBP-1(U) mRNA that acts as a dominant negative of endogenous XBP-1(S) action. In cancer cells, overexpression of XBP-1 can confer drug resistance by preventing drug-induced cell-cycle arrest and mitochondrial permeability and apoptosis, while downregulation of XBP-1 increases the sensitivity to killing by hypoxia. XBP-1 is also implicated in cellular de-differentiation, oncovirus infection and the epithelial-to-mesenchymal transition. Given that XBP-1 mediates a wide range of responses in tumorigenesis, it is logical to focus on XBP-1 as an anticancer therapeutic target. Furthermore, combining inhibitors of XBP-1 with other anti-UPR drugs may enhance the activity of some antineoplastic therapies. Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609461      PMCID: PMC3510657          DOI: 10.1358/dnp.2009.22.5.1378631

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  73 in total

Review 1.  The unfolded protein response in nutrient sensing and differentiation.

Authors:  Randal J Kaufman; Donalyn Scheuner; Martin Schröder; Xiaohua Shen; Kyungho Lee; Chuan Yin Liu; Stacey M Arnold
Journal:  Nat Rev Mol Cell Biol       Date:  2002-06       Impact factor: 94.444

Review 2.  Transcriptional and translational control in the Mammalian unfolded protein response.

Authors:  Heather P Harding; Marcella Calfon; Fumihiko Urano; Isabel Novoa; David Ron
Journal:  Annu Rev Cell Dev Biol       Date:  2002-04-02       Impact factor: 13.827

3.  Molecular classification of primary breast tumors possessing distinct prognostic properties.

Authors:  Kyoko Iwao; Ryo Matoba; Noriko Ueno; Akiko Ando; Yasuo Miyoshi; Kenichi Matsubara; Shinzaburo Noguchi; Kikuya Kato
Journal:  Hum Mol Genet       Date:  2002-01-15       Impact factor: 6.150

4.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

5.  IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA.

Authors:  Marcella Calfon; Huiqing Zeng; Fumihiko Urano; Jeffery H Till; Stevan R Hubbard; Heather P Harding; Scott G Clark; David Ron
Journal:  Nature       Date:  2002-01-03       Impact factor: 49.962

6.  IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response.

Authors:  Kyungho Lee; Witoon Tirasophon; Xiaohua Shen; Marek Michalak; Ron Prywes; Tetsuya Okada; Hiderou Yoshida; Kazutoshi Mori; Randal J Kaufman
Journal:  Genes Dev       Date:  2002-02-15       Impact factor: 11.361

7.  XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor.

Authors:  H Yoshida; T Matsui; A Yamamoto; T Okada; K Mori
Journal:  Cell       Date:  2001-12-28       Impact factor: 41.582

8.  Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis.

Authors:  Masahiro Shuda; Nobuo Kondoh; Nobuo Imazeki; Kenji Tanaka; Tetsuya Okada; Kazutoshi Mori; Akiyuki Hada; Masaaki Arai; Toru Wakatsuki; Osamu Matsubara; Naoki Yamamoto; Mikio Yamamoto
Journal:  J Hepatol       Date:  2003-05       Impact factor: 25.083

9.  Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).

Authors:  Zhiping Gu; Richard Y Lee; Todd C Skaar; Kerrie B Bouker; James N Welch; Jianping Lu; Aiyi Liu; Yuelin Zhu; Natalie Davis; Fabio Leonessa; Nils Brünner; Yue Wang; Robert Clarke
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

10.  Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.

Authors:  Ann-Hwee Lee; Neal N Iwakoshi; Kenneth C Anderson; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-05       Impact factor: 11.205

View more
  31 in total

1.  Mutual cross talk between the regulators Hac1 of the unfolded protein response and Gcn4 of the general amino acid control of Saccharomyces cerevisiae.

Authors:  Britta Herzog; Blagovesta Popova; Antonia Jakobshagen; Hedieh Shahpasandzadeh; Gerhard H Braus
Journal:  Eukaryot Cell       Date:  2013-06-21

2.  Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death.

Authors:  Katherine L Cook; Pamela A G Clarke; Jignesh Parmar; Rong Hu; Jessica L Schwartz-Roberts; Mones Abu-Asab; Anni Wärri; William T Baumann; Robert Clarke
Journal:  FASEB J       Date:  2014-05-23       Impact factor: 5.191

Review 3.  Autophagy and endocrine resistance in breast cancer.

Authors:  Katherine L Cook; Ayesha N Shajahan; Robert Clarke
Journal:  Expert Rev Anticancer Ther       Date:  2011-08       Impact factor: 4.512

4.  Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells.

Authors:  Sara Sannino; Christopher J Guerriero; Amit J Sabnis; Donna Beer Stolz; Callen T Wallace; Peter Wipf; Simon C Watkins; Trever G Bivona; Jeffrey L Brodsky
Journal:  J Cell Sci       Date:  2018-09-05       Impact factor: 5.285

Review 5.  Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate.

Authors:  Robert Clarke; Katherine L Cook; Rong Hu; Caroline O B Facey; Iman Tavassoly; Jessica L Schwartz; William T Baumann; John J Tyson; Jianhua Xuan; Yue Wang; Anni Wärri; Ayesha N Shajahan
Journal:  Cancer Res       Date:  2012-03-15       Impact factor: 12.701

6.  Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells.

Authors:  Feng-Ming Wang; Deborah L Galson; G David Roodman; Hongjiao Ouyang
Journal:  Exp Hematol       Date:  2011-07-01       Impact factor: 3.084

7.  Acridine Derivatives as Inhibitors of the IRE1α-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma.

Authors:  Dadi Jiang; Arvin B Tam; Muthuraman Alagappan; Michael P Hay; Aparna Gupta; Margaret M Kozak; David E Solow-Cordero; Pek Y Lum; Nicholas C Denko; Amato J Giaccia; Quynh-Thu Le; Maho Niwa; Albert C Koong
Journal:  Mol Cancer Ther       Date:  2016-06-15       Impact factor: 6.261

8.  Activation of unfolded protein response protects osteosarcoma cells from cisplatin-induced apoptosis through NF-κB pathway.

Authors:  Mingming Yan; Jiangdong Ni; Deye Song; Muliang Ding; Jun Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 9.  Molecular Pathways: Immunosuppressive Roles of IRE1α-XBP1 Signaling in Dendritic Cells of the Tumor Microenvironment.

Authors:  Juan R Cubillos-Ruiz; Sarah E Bettigole; Laurie H Glimcher
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

10.  Targeting abnormal ER stress responses in tumors: A new approach to cancer immunotherapy.

Authors:  Juan R Cubillos-Ruiz; Laurie H Glimcher
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.